Mark Goldsmith Sells 15,394 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Mark Goldsmith sold 15,394 shares of Revolution Medicines stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total transaction of $1,182,567.08. Following the completion of the sale, the insider owned 232,469 shares in the company, valued at approximately $17,858,268.58. This trade represents a 6.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Revolution Medicines Stock Up 3.7%

RVMD opened at $78.78 on Friday. The company has a market cap of $15.23 billion, a PE ratio of -15.24 and a beta of 0.96. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $81.49. The company has a 50-day moving average price of $66.73 and a 200 day moving average price of $49.21. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same period in the prior year, the business posted ($0.94) earnings per share. Sell-side analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Institutional Trading of Revolution Medicines

Several institutional investors have recently made changes to their positions in RVMD. FNY Investment Advisers LLC purchased a new position in Revolution Medicines in the third quarter worth approximately $110,000. Swiss Life Asset Management Ltd acquired a new position in shares of Revolution Medicines in the 3rd quarter valued at $293,000. Danske Bank A S purchased a new position in shares of Revolution Medicines during the 3rd quarter worth $98,000. TCG Crossover Management LLC acquired a new stake in shares of Revolution Medicines during the 3rd quarter worth about $20,383,000. Finally, Sender Co & Partners Inc. purchased a new stake in Revolution Medicines in the 3rd quarter valued at about $403,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: First patient randomized in RASolute‑304 (daraxonrasib) resectable pancreatic cancer trial — a near‑term clinical milestone that validates program progress and can support longer‑term revenue potential if subsequent data are positive. Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial
• Neutral Sentiment: Analyst coverage remains largely positive (consensus Buy/Strong Buy with an average target near $78.50), which provides support for the stock but already factors in pipeline strengths.
• Neutral Sentiment: Institutional ownership is very high (reported ~94%); recent reported changes were small. High institutional concentration can amplify moves on news but also limits free float liquidity. RVMD Institutional Ownership and Stock Profile
• Negative Sentiment: Several insiders sold meaningful share blocks (CFO Jack Anders, COO Margaret Horn and other executives sold on Dec. 16), which can be interpreted as profit‑taking or a signal for caution; aggregated insider selling may weigh on sentiment near term. Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 3,104 Shares of Stock

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Needham & Company LLC lifted their target price on shares of Revolution Medicines from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. UBS Group raised shares of Revolution Medicines to a “strong-buy” rating in a research note on Thursday, December 4th. Wedbush increased their price objective on shares of Revolution Medicines from $77.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Truist Financial initiated coverage on Revolution Medicines in a report on Friday, September 5th. They set a “buy” rating and a $99.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their price target on Revolution Medicines from $71.00 to $82.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $78.50.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.